Chronic pain is pain that is ongoing and usually lasts longer than six months. This type of pain can continue even after the injury or illness that caused it has healed or gone away. Pain signals remain active in the nervous system for weeks, months or years. Chronic pain is linked to conditions that include: Headache, Arthitis, Cancer, Nerve pain, Back pain, Fibromyalgia. Chronic pain also causes emotional effects, including: Depression, Anger, Anxiety. Drugs prescribed for the treatment of chronic pain are opioids, non-steroidal anti-inflammatory drugs (NSAIDS), anticonvulsants, antidepressants and others.
Market Dynamics
Key players are focused on product launches in order to expand their product portfolio. This is expected to propel the growth of the global chronic pain market during the forecast period. For instance, in February 2016, Endo Pharmaceuticals Inc., a subsidiary of Endo International plc, announced the availability of BELBUCA (buprenorphine) buccal film, the first and only buprenorphine formulation developed with a dissolving film that is absorbed through the inner lining of the cheek for chronic pain management. BELBUCA, distributed and promoted by Endo, is now available United States.
Increasing number of positive results of drugs is the major factor driving the market growth over the forecast period. For instance, in April 2017, VistaGen Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced the peer-reviewed publication of nonclinical studies of the effects of AV-101 (4-Cl-KYN), its CNS product candidate, in four well-established nonclinical models of pain.
Key features of the study:
- This report provides an in-depth analysis of global chronic pain market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global chronic pain market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
- Key companies covered as a part of this study include Eli Lilly and Company, GlaxoSmithKline plc., Pfizer Inc , Abbott Laboratories, Novartis AG, Johnson & Jonson, AstraZeneca plc, Bristol-Myers Squibb Company, Becton, Dickinson and Company, and Sanofi S.A..
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global chronic pain market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the Smart market
Detailed Segmentation:
- Global Chronic Pain Market, By Drugs:
- Opioids
- Non- Steroidal anti- inflammatory drugs (NSAIDS)
- Anticonvulsants
- Anti drepressants
- Others
- Global Chronic Pain Market, By Indication:
- Neuropathic Pain
- Arthritis Pain
- Chronic Back pain
- Cancer pain
- Migraine
- Fibromyalgia
- Others
- Global Chronic Pain Market, By Application
- Musculoskeletal
- Neuropathy
- Oncology
- Others
- Global Chronic Pain Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Chronic Pain Market, By Region:
- North America
- By Drugs:
- Opioids
- Non-steroidal anti-inflammatory drugs (NSAIDS)
- Anticonvulsants
- Antidepressants
- Others
- By Indication:
- Neuropathic Pain
- Arthritis Pain
- Chronic Back Pain
- Cancer Pain
- Migraine
- Fibromyalgia
- Others
- By Application:
- Musculoskeletal
- Neuropathy
- Oncology
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Latin America
- By Drugs:
- Opioids
- Non-steroidal anti-inflammatory drugs (NSAIDS)
- Anticonvulsants
- Antidepressants
- Others
- By Indication:
- Neuropathic Pain
- Arthritis Pain
- Chronic Back Pain
- Cancer Pain
- Migraine
- Fibromyalgia
- Others
- By Application:
- Musculoskeletal
- Neuropathy
- Oncology
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Drugs:
- Opioids
- Non-steroidal anti-inflammatory drugs (NSAIDS)
- Anticonvulsants
- Antidepressants
- Others
- By Indication:
- Neuropathic Pain
- Arthritis Pain
- Chronic Back Pain
- Cancer Pain
- Migraine
- Fibromyalgia
- Others
- By Application:
- Musculoskeletal
- Neuropathy
- Oncology
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
- By Drugs:
- Opioids
- Non-steroidal anti-inflammatory drugs (NSAIDS)
- Anticonvulsants
- Antidepressants
- Others
- By Indication:
- Neuropathic Pain
- Arthritis Pain
- Chronic Back Pain
- Cancer Pain
- Migraine
- Fibromyalgia
- Others
- By Application:
- Musculoskeletal
- Neuropathy
- Oncology
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Middle East
- By Drugs:
- Opioids
- Non-steroidal anti-inflammatory drugs (NSAIDS)
- Anticonvulsants
- Antidepressants
- Others
- By Indication:
- Neuropathic Pain
- Arthritis Pain
- Chronic Back Pain
- Cancer Pain
- Migraine
- Fibromyalgia
- Others
- By Application:
- Musculoskeletal
- Neuropathy
- Oncology
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drugs:
- Opioids
- Non-steroidal anti-inflammatory drugs (NSAIDS)
- Anticonvulsants
- Antidepressants
- Others
- By Indication:
- Neuropathic Pain
- Arthritis Pain
- Chronic Back Pain
- Cancer Pain
- Migraine
- Fibromyalgia
- Others
- By Application:
- Musculoskeletal
- Neuropathy
- Oncology
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Eli Lilly and Company *
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- GlaxoSmithKline plc.
- Pfizer Inc.
- Abbott Laboratories
- Novartis AG
- Johnson & Johnson
- AstraZeneca plc.
- Bristol-Myers Squibb Company
- Becton, Dickinson and Company
- Sanofi S.A.
“*” marked represents similar segmentation in other categories in the respective section.
